Therapeutic drug monitoring of biologics in psoriasis

MeiQi May Liau,1 Hazel H Oon2 1Division of Dermatology, University Medicine Cluster, National University Hospital, Singapore; 2National Skin Centre, Singapore Abstract: Biologics are an important component of the armamentarium of drugs in the treatment of moderate to severe psoriasis. There is incre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liau MM, Oon HH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Psoriasis biologics therapeutic drug monitoring Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4a83dcd05d60494a96d64cc42677a1d7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4a83dcd05d60494a96d64cc42677a1d7
record_format	dspace
spelling	oai:doaj.org-article:4a83dcd05d60494a96d64cc42677a1d72021-12-02T05:31:56ZTherapeutic drug monitoring of biologics in psoriasis1177-5491https://doaj.org/article/4a83dcd05d60494a96d64cc42677a1d72019-07-01T00:00:00Zhttps://www.dovepress.com/therapeutic-drug-monitoring-of-biologics-in-psoriasis-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491MeiQi May Liau,1 Hazel H Oon2 1Division of Dermatology, University Medicine Cluster, National University Hospital, Singapore; 2National Skin Centre, Singapore Abstract: Biologics are an important component of the armamentarium of drugs in the treatment of moderate to severe psoriasis. There is increasing evidence that therapeutic drug monitoring (TDM) encompassing the measurement of trough concentrations and anti-drug antibodies (ADA), together with clinical response is emerging as a valuable tool for clinical decision making. It aids in targeted dose adjustments in patients with low drug concentrations, monitoring of adherence and assessment of patients who lose response to biologics or do not respond at all. The high prevalence of psoriasis, its impact on patients’ lives and costs spent on therapy motivate an evidence-based and cost-effective utility of biologics. We performed a literature review on the TDM of TNF alpha antagonists (adalimumab, infliximab, etanercept), IL12/23 antagonists (ustekinumab, guselkumab, tildrakizumab), IL17A inhibitors (secukinumab, ixekizumab) and biosimilars used in the treatment of psoriasis. Although establishing target therapeutic ranges for biologics is ideal, this has only been explored in adalimumab. We also propose a treatment algorithm for the practical application of TDM depending on drug trough concentrations, presence/absence of anti-drug antibodies and clinical response of patients. The practice of TDM is recommended in routine clinical practice where possible. Keywords: psoriasis, biologics, therapeutic drug monitoringLiau MMOon HHDove Medical PressarticlePsoriasisbiologicstherapeutic drug monitoringMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 13, Pp 127-132 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Psoriasis biologics therapeutic drug monitoring Medicine (General) R5-920
spellingShingle	Psoriasis biologics therapeutic drug monitoring Medicine (General) R5-920 Liau MM Oon HH Therapeutic drug monitoring of biologics in psoriasis
description	MeiQi May Liau,1 Hazel H Oon2 1Division of Dermatology, University Medicine Cluster, National University Hospital, Singapore; 2National Skin Centre, Singapore Abstract: Biologics are an important component of the armamentarium of drugs in the treatment of moderate to severe psoriasis. There is increasing evidence that therapeutic drug monitoring (TDM) encompassing the measurement of trough concentrations and anti-drug antibodies (ADA), together with clinical response is emerging as a valuable tool for clinical decision making. It aids in targeted dose adjustments in patients with low drug concentrations, monitoring of adherence and assessment of patients who lose response to biologics or do not respond at all. The high prevalence of psoriasis, its impact on patients’ lives and costs spent on therapy motivate an evidence-based and cost-effective utility of biologics. We performed a literature review on the TDM of TNF alpha antagonists (adalimumab, infliximab, etanercept), IL12/23 antagonists (ustekinumab, guselkumab, tildrakizumab), IL17A inhibitors (secukinumab, ixekizumab) and biosimilars used in the treatment of psoriasis. Although establishing target therapeutic ranges for biologics is ideal, this has only been explored in adalimumab. We also propose a treatment algorithm for the practical application of TDM depending on drug trough concentrations, presence/absence of anti-drug antibodies and clinical response of patients. The practice of TDM is recommended in routine clinical practice where possible. Keywords: psoriasis, biologics, therapeutic drug monitoring
format	article
author	Liau MM Oon HH
author_facet	Liau MM Oon HH
author_sort	Liau MM
title	Therapeutic drug monitoring of biologics in psoriasis
title_short	Therapeutic drug monitoring of biologics in psoriasis
title_full	Therapeutic drug monitoring of biologics in psoriasis
title_fullStr	Therapeutic drug monitoring of biologics in psoriasis
title_full_unstemmed	Therapeutic drug monitoring of biologics in psoriasis
title_sort	therapeutic drug monitoring of biologics in psoriasis
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/4a83dcd05d60494a96d64cc42677a1d7
work_keys_str_mv	AT liaumm therapeuticdrugmonitoringofbiologicsinpsoriasis AT oonhh therapeuticdrugmonitoringofbiologicsinpsoriasis
_version_	1718400349553819648

Therapeutic drug monitoring of biologics in psoriasis

Ejemplares similares